|
|
 |
| |
|
Home > Drug Companies > Biogen, Inc.
Biogen, Inc.
In June 2003, Biogen and IDEC Pharmaceuticals announced their agreement to merge. This merger was finalized in November 2003, creating Biogen Idec, the third-largest biotechnology company in the world. The company is a NASDAQ-traded firm listed under the symbol BIIB.
Each company has a track record of success in the development, manufacture and commercialization of novel, first in class products that significantly improve human healthcare.
Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader with leading products and capabilities in oncology, neurology and immunology, is committed to transforming scientific discovery into advances in healthcare. The company's core capabilities include drug discovery, research, development, biomanufacturing and a global commercial infrastructure.
Biogen Idec pursues the creativity of science with passion and discipline. For more than 25 years, the company has grown through the discovery, development and commercialization of its own innovative products and through strategic alliances.
Scientific excellence that achieves new standards of care drives the company's work. 15 products are currently in clinical development addressing a variety of key medical needs.
At Biogen Idec, they are driven to create new standards in human healthcare. In their effort to achieve this ideal they recognize the need to enhance their own innovative research and development activities with collaborative, long term partnerships.
Successful partnerships are the reason Biogen Idec is a leader in biotechnology. As they look toward the future, they are actively seeking alliance opportunities in specialty markets, especially in their core therapeutic areas in neurology, oncology, dermatology, and rheumatology. They are interested in leveraging their broad expertise in biologics and expanding their capabilities in small molecules.
Biogen Idec's Business Development group aims to be flexible and creative, responding to potential partners quickly and thoughtfully. Their BD teams in San Diego, Cambridge, Tokyo and Europe work together to ensure that opportunities receive proper attention.
Partnering opportunities are first screened for strategic fit with their therapeutic areas of interest. Further evaluation is done by their Alliance Review Committees therapeutically focused panels that evaluate opportunities from a clinical, scientific, legal and commercial perspective. This cross functional evaluation provides for senior management endorsement early in the process, helping to expedite subsequent partnering discussions.
Back to Drug Companies
|
|
|
|
|
|
|
|